Deep, qualified next-generation sequencing has unveiled that subclonal mutations (i.e., These existing in only a fraction of tumor cells) can be detected for all driver genes and are linked to swift disorder development and poor outcome.11–13 This is particularly suitable for TP53) and incorporated into these prognostic devices, but none of these